Neutralization of low molecular weight heparin by polybrene prevents thromboxane release and severe pulmonary hypertension in awake sheep.

Protamine reversal of heparin anticoagulation in patients is occasionally associated with life-threatening acute pulmonary hypertension. In a sheep model, we evaluated the effect on this adverse cardiopulmonary reaction of modifying the type of heparin (low molecular weight heparin compared with unfractionated heparin) and the type of heparin antagonist (polybrene compared with protamine). Protamine reversal of low molecular weight heparin (LMWH) and polybrene reversal of unfractionated heparin induced more than a 10-fold increase of plasma thromboxane B2 levels, a threefold increase of pulmonary vascular resistance and pulmonary artery pressure, and a 25% decrease of PaO2. A similar adverse reaction followed protamine reversal of conventional unfractionated heparin. However, with polybrene (1 mg/kg) reversal of LMWH (1 mg/kg), we measured neither pulmonary hypertension (pulmonary artery pressure was 22.6 +/- 3.6 mm Hg at 1 minute after polybrene reversal of LMWH compared with 47.9 +/- 4.2 mm Hg after protamine reversal of unfractionated heparin, p less than 0.005 groups differ), hypoxemia (PaO2 was unchanged 2 minutes after polybrene compared with a decrease of 26 mm Hg 2 minutes after protamine, p less than 0.05), nor acute release of thromboxane into arterial plasma (thromboxane B2 was 0.2 +/- 0.1 at 1 minute after polybrene compared with 3.7 +/- 1.7 ng/ml at 1 minute after protamine, p less than 0.005). The hemodynamic effects and mediator release were also benign after neutralization of larger doses of LMWH (3 mg/kg) by polybrene (3 mg/kg). The increases of activated clotting time and activated partial thromboplastin time due to both types of heparin were completely reversed with polybrene. Anti-Xa activity increased to more than 3 IU/ml 4 minutes after LMWH anticoagulation (p less than 0.01) but was only partially neutralized by polybrene. Various polyanion-polycation complexes that are formed when heparin anticoagulation is reversed induce thromboxane release and acute pulmonary vasoconstriction in awake sheep. Reversal of LMWH anticoagulation with polybrene does not elicit this adverse reaction.

[1]  G. Montalescot,et al.  Effect of platelet depletion on lung vasoconstriction in heparin-protamine reactions. , 1989, Journal of applied physiology.

[2]  C. Hirshman,et al.  Association of protamine IgE and IgG antibodies with life-threatening reactions to intravenous protamine. , 1989, The New England journal of medicine.

[3]  D. Dehring,et al.  Intravascular macrophages in pulmonary capillaries of humans. , 1989, The American review of respiratory disease.

[4]  R. Gutmann,et al.  Thromboxane Mediation of Pulmonary Hemodynamic Responses after Neutralization of Heparin by Protamine in Pigs , 1989, Anesthesia and analgesia.

[5]  J. Repine,et al.  Acute Pulmonary Vasoconstriction and Thromboxane Release During Protamine Reversal of Heparin Anticoagulation in Awake Sheep: Evidence for the Role of Reactive Oxygen Metabolites Following Nonimmunological Complement Activation , 1988, Circulation research.

[6]  K. Peter,et al.  Beneficial Effect of Cyclooxygenase Inhibition on Adverse Hemodynamic Responses after Protamine , 1988, Anesthesia and analgesia.

[7]  M. Mitchell,et al.  Pulmonary intravascular macrophages and hemodynamic effects of liposomes in sheep. , 1988, Journal of applied physiology.

[8]  T. Wakefield,et al.  Protamine reversal of anticoagulation achieved with a low molecular weight heparin. The effects on eicosanoids, clotting and complement factors. , 1987, Thrombosis research.

[9]  S. Thomas,et al.  C5a and thromboxane generation associated with pulmonary vaso- and broncho-constriction during protamine reversal of heparin. , 1987, Anesthesiology.

[10]  P. Ostergaard,et al.  Neutralization of a Low Molecular Weight Heparin (LHN-1) and Conventional Heparin by Protamine Sulfate in Rats , 1986, Thrombosis and Haemostasis.

[11]  E. Salzman.  Low-Molecular-Weight Heparin , 1986 .

[12]  J. Brain,et al.  Pulmonary intravascular macrophages in sheep. Morphology and function of a novel constituent of the mononuclear phagocyte system. , 1986, Laboratory investigation; a journal of technical methods and pathology.

[13]  J. Fiessinger,et al.  Heparin-Associated Thrombocytopenia Treatment with Low Molecular Weight Heparin , 1986, Thrombosis and Haemostasis.

[14]  G. Bratt,et al.  A Comparison Between Low Molecular Weight Heparin (KABI 2165) and Standard Heparin in the Intravenous Treatment of Deep Venous Thrombosis , 1985, Thrombosis and Haemostasis.

[15]  R. Read,et al.  Cardiovascular effects of protamine sulfate are dependent on the presence and type of circulating heparin. , 1985, The Journal of thoracic and cardiovascular surgery.

[16]  H. Büller,et al.  A randomized blind study comparing standard heparin and a new low molecular weight heparinoid in cardiopulmonary bypass surgery in dogs. , 1985, The Journal of laboratory and clinical medicine.

[17]  S. Shankel,et al.  Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function. , 1985, The American journal of medicine.

[18]  A. Gnasso,et al.  Inhibition of low molecular weight heparin by protamine chloride in vivo. , 1985, Thrombosis research.

[19]  J. Horrow.  Protamine: A Review of its Toxicity , 1985, Anesthesia and analgesia.

[20]  A. Hubbard,et al.  Neutralisation of Heparan Sulphate and Low Molecular Weight Heparin by Protamine , 1985, Thrombosis and Haemostasis.

[21]  A. Carpentier,et al.  LOW-MOLECULAR-WEIGHT HEPARIN IN EXTRACORPOREAL CIRCULATION , 1984, The Lancet.

[22]  J. Fehr,et al.  In vivo complement activation by polyanion--polycation complexes: evidence that C5a is generated intravascularly during heparin--protamine interaction. , 1983, Clinical immunology and immunopathology.

[23]  L. Axelrod,et al.  Plasma Prostaglandin Levels in Rats with Diabetes Mellitus and Diabetic Ketoacidosis , 1982, Diabetes.

[24]  M. Poon,et al.  Platelet Factor Four and Protamine Sulfate Neutralization of Heparin Fractionated According to Anionic Charge Density , 1982, Thrombosis and Haemostasis.

[25]  C. Mattsson,et al.  Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits. , 1982, Thrombosis research.

[26]  T. Barrowcliffe,et al.  Anticoagulant Activities of High and Low Molecular Weight Heparin Fractions , 1979, British journal of haematology.

[27]  E. Foster,et al.  Polybrene neutralization as a means of monitoring heparin therapy for extracoporeal cirulation. , 1977, The Annals of thoracic surgery.

[28]  M. Lie,et al.  Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III. , 1977, Thrombosis research.

[29]  M. K. Sykes,et al.  Pulmonary vasoconstriction produced by protamine and protamine-heparin complex in the isolated cat lung perfused with blood or dextran. , 1975, Cardiovascular research.

[30]  M. Hamberg,et al.  Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[31]  J. Keneally,et al.  Changes in Serum Potassium after Suxamethonium in Children , 1974, Anaesthesia and intensive care.

[32]  P. Hattersley.  Activated coagulation time of whole blood. , 1966, JAMA.

[33]  J. Haller,et al.  RENAL TOXICITY OF POLYBRENE, (HEXADIMETHRINE BROMIDE). , 1965, The Journal of surgical research.

[34]  J. Haller,et al.  RENAL TOXICITY OF POLYBRENE IN OPEN-HEART SURGERY , 1962 .

[35]  R. R. Proctor,et al.  The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies. , 1961, American journal of clinical pathology.

[36]  D. Cooley,et al.  Relative antiheparin potency of polybrene and protamine in patients undergoing extracorporeal circulation. , 1959, The Journal of thoracic and cardiovascular surgery.

[37]  A. E. Osterberg,et al.  Heparin neutralization with polybrene administered intravenously. , 1958, Journal of the American Medical Association.

[38]  S. Ferraris,et al.  Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting. , 1988, The Annals of thoracic surgery.

[39]  A. Carpentier,et al.  Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation. , 1986, Haemostasis.

[40]  E. Salzman.  Low-molecular-weight heparin: is small beautiful? , 1986, The New England journal of medicine.

[41]  J. D. Morris,et al.  Acute reaction to protamine. Its importance to surgeons. , 1984, The American surgeon.

[42]  M. Petitou,et al.  Binding of heparin and low molecular weight heparin fragments to human vascular endothelial cells in culture. , 1984, Nouvelle revue francaise d'hematologie.

[43]  P. Henson,et al.  Biologial effects of the human complement fragments C5a and C5ades Arg on neutrophil function. , 1980, Immunopharmacology.

[44]  H. Gewurz,et al.  Complement activation by interaction of polyanions and polycations. III. Complement activation by interaction of multiple polyanious and polycations is the presence of C-reactive protein. , 1977, Journal of immunology.

[45]  H. Godal,et al.  A comparison of two heparin-neutralizing agents: protamine and polybrene. , 1960, Scandinavian journal of clinical and laboratory investigation.